The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO MAP 2022 | TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) (TRACERx)
Robert Hynds, PhD, UCL, London, UK, talks on the TRACERx (NCT01888601) study aiming to characterize tumor heterogeneity in a cohort of patients with non-small cell lung cancer (NSCLC). Dr Hynds provides an overview of his role in TRACERx involving the development of patient-derived xenograft (PDX) models derived from multiple regions of primary NSCLC from patients in lung TRACERx to assess the fidelity of PDX models as a surrogate for the patients’ tumor. https://www.biorxiv.org/content/10.1101/2023.01.06.521078v1.full. This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
